Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns Overweight Rating from Analysts at Barclays

Barclays initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note published on Wednesday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $527.00 price objective on the biopharmaceutical company’s stock.

ALNY has been the topic of a number of other research reports. Stifel Nicolaus increased their price target on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Jefferies Financial Group decreased their target price on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a research report on Thursday, October 30th. HC Wainwright set a $570.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 4th. Truist Financial reduced their price objective on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research report on Thursday, January 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $489.00 price objective (up from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Twenty-two analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $477.13.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $338.06 on Wednesday. The company has a market capitalization of $44.66 billion, a PE ratio of 1,408.58 and a beta of 0.32. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. The company’s fifty day moving average price is $399.61 and its 200 day moving average price is $423.63. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $495.55.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,510 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70. Following the transaction, the executive vice president directly owned 29,728 shares in the company, valued at approximately $10,787,399.36. The trade was a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the company’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total transaction of $848,055.70. Following the sale, the executive vice president directly owned 21,264 shares of the company’s stock, valued at approximately $7,874,697.12. This represents a 9.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 56,955 shares of company stock worth $24,072,733 over the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after purchasing an additional 268,313 shares during the last quarter. Capital Research Global Investors grew its holdings in Alnylam Pharmaceuticals by 0.4% in the 3rd quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock valued at $3,293,516,000 after buying an additional 31,184 shares in the last quarter. Groupama Asset Managment increased its stake in shares of Alnylam Pharmaceuticals by 160.4% in the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after acquiring an additional 2,483,697 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after acquiring an additional 75,936 shares during the last quarter. Finally, Orbis Allan Gray Ltd raised its holdings in shares of Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after acquiring an additional 486,489 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Barclays initiated coverage with an overweight (positive) recommendation — new institutional attention and an overweight start can attract buyers and support the share price. Barclays Initiates Coverage on Alnylam
• Positive Sentiment: Bank of America lowered its price target from $529 to $462 but maintained a Buy rating (implies ~36.7% upside vs. current price), which is supportive versus a full downgrade. BofA PT cut to $462
• Positive Sentiment: HC Wainwright cut its target from $570 to $510 but kept a Buy rating (implies ~50.9% upside), another vote of confidence from a sell-side firm. HC Wainwright PT cut to $510
• Positive Sentiment: Alnylam outlined a new five‑year strategy, “Alnylam 2030,” and is projecting ~ $5.3B revenue for 2026 — strategic growth targets and a multi‑year plan can support investor confidence in long‑term upside. Alnylam projects 2026 revenue ~$5.3B
• Neutral Sentiment: Alnylam will webcast a conference call to discuss Q4 and full‑year 2025 results — standard corporate event that may move the stock depending on actual results and guidance. Webcast of Q4/FY2025 results
• Neutral Sentiment: Reported short‑interest data shows effectively zero reported short position (data appears inconsistent/placeholder); this item is unlikely to explain intraday moves. (Internal short‑interest report)
• Negative Sentiment: Morgan Stanley lowered its price target from $495 to $408 and moved to an Equal Weight rating — a visible downgrade in sentiment from a major bank which likely pressured the stock. Morgan Stanley PT cut to $408
• Negative Sentiment: Technical context: the stock is trading below both its 50‑day (~$401.57) and 200‑day (~$423.47) moving averages, which can amplify downside as trend‑following and momentum flows react.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.